Monday, November 28, 2011, 3105 Etcheverry Hall, 4-5pm
EM2 and Spinoff Technologies
Senior Scientist for Advanced Reactors
EM2 is a helium-cooled fast reactor with a conversion ratio of near unity. It has a 30 year core life and is able to burn spent LWR fuel without reprocessing. An update of the technical developments in EM2 since the last Berkeley colloquium will be given. The update will include design changes and improvements as well as progress on fuel fabrication and SiC composite development. EM2 has fostered a number of spinoff technologies that are actively being pursued including SiC composite clad for LWRs, high-speed turbo-generators and EM3, a small, molten-salt cooled, autonomous version of EM2.
October 3, 2011 at 4pm: 3105 Etcheverry Hall
Neutrons emitted following the beta decay of fission fragments play an important role in many fields of basic and applied science such as nuclear energy, nuclear astrophysics, and stockpile stewardship. However, the fundamental nuclear data available today for individual nuclei is limited – for the vast majority of neutron emitters, the energy spectrum has not been measured and some recent measurements have uncovered discrepancies as large as factors of 2-4 in beta-delayed neutron branching ratios. Radioactive ions held in an ion trap are an appealing source of activity for improved studies of this beta-delayed neutron emission process. When a radioactive ion decays in the trap, the recoiling daughter nucleus and emitted radiation emerges from the ~1 mm3 trap volume and propagates through vacuum without scattering. Information about particles that are difficult or even impossible to detect can be obtained using conservation of momentum/energy from the determination of the nuclear recoil and beta particle kinematics. For the first time, beta-delayed neutron spectroscopy is being performed using trapped ions by identifying neutron emission from the large nuclear recoil it imparts and using this recoil energy to reconstruct the neutron branching ratios and energy spectra. Results from a recent proof-of-principle measurement of the beta-delayed neutron spectrum of Iodine-137 and plans for future experiments at Argonne National Laboratory using significantly higher intensity fission-fragment beams will be presented.
This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.
Jean Pouliot, UC San Francisco
Radiation therapy, alone or in combination with other modalities, is involved in the treatment of a majority of cancers, is practiced in every clinic and used to treat practically every site of the body. The field of radiation oncology is a perfect example of a multidisciplinary environment requiring expertise of people from widely different backgrounds. In order to control the tumor and cure the cancer patient, one needs to deliver a high dose to cancer cells, drawing on concepts related to radiation, energy, radiobiology, imaging, computation and statistics. By understanding those concepts, the medical physicist plays a key role and allows the team members to safely and effectively use radiation in the treatment of cancer.
September 19, 2011
The proposed Materials Test Station, to be built at the Los Alamos Neutron Science Center, will use the high-power proton beam from the LANSCE accelerator to create an intense neutron irradiation environment for nuclear materials testing. The primary mission is to test advanced fuels and materials for fast reactor applications, including fuels bearing minor actinides, in support of the DOE Office of Nuclear Energy's Fuel Cycle R&D program. Damage rates of up to 15 dpa per year in iron can be achieved within the fuel irradiation region. Not only can the MTS perform integral testing of fuel rodlets subjected to prototypic fast reactor conditions, it is also well suited to conducting separate effects experiments that are critically important to understanding the underlying processes that contribute to fuel aging and ultimately fuel failure. Separate effects testing of the type than can be conducted in MTS can validate modeling efforts that are used to simulate fuel performance.
Location is 3105 Etcheverry Hall; Cookies and Coffee served at 3:45.
TODAY, September 12, 2011. Location is 3105 Etcheverry Hall; Cookies and Coffee served at 3:45.
At Lawrence Berkeley National Laboratory (LBNL) there is a long and distinguished history in the development of accelerator-based synchrotron light and ion beam cancer therapy (IBCT) facilities. LBNL built and commissioned the Advanced Light Source (ALS), the world’s first soft X-ray third generation light source in early 1990s, that is currently the world’s brightest source of soft X-rays. In addition to the ALS, extensive work is underway directed at the development of the next generation of Free Electron Lasers (FELs). With the success of the ALS and the consolidated FEL R&D activities, LBNL is well positioned to host a soft X-ray FEL of unprecedented brightness. In the area of ion beam cancer therapy, LBNL also has a distinguished history. The field of IBCT was pioneered at LBNL in the 1950s. In subsequent years, 4,000 patients were treated using protons or heavier ions such as carbon. Worldwide IBCT is currently a rapidly expanding field with nearly 100,000 patients having been treated. Presently at LBNL, R&D is underway to develop technologies to improve ion beam cancer therapy that might significantly improve the performance or reduce the cost of treatment. In this talk, Dr. Robin will briefly describe the present research activities, and future prospects in light sources and ion beam cancer therapy.